Pharmaceutical - Johnson & Johnson, Takeda Pharmaceuticals

Filter

Popular Filters

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Improved symptom control and quality of life among greatest unmet needs in metastatic-resistant prostate cancer therapy

06-06-2013

Symptom control and quality of life is one of the factors the most influences surveyed US and European…

BayerCometriqEuropeExelixisJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyorteronelPharmaceuticalTakeda PharmaceuticalsXofigoZytiga

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers

06-01-2013

A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches

16-12-2012

The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

Regulatory briefs on vortioxetine, canagliflozin/metformin combo and Rescula

13-12-2012

Takeda Global Research & Development Center, a unit of Japanese drug giant Takeda Pharma's (TYO: 4502),…

BrintellixcanagliflozinDiabetesJanssenJohnson & JohnsonLundbeckmetforminNeurologicalNorth AmericaOphthalmicsPharmaceuticalRegulationResculaSucampoTakeda Pharmaceuticalsvortioxetine

Multiple myeloma drug market forecast to reach $7.2 billion in 2021

03-10-2012

The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

CHMP positive on first gene therapy, Glybera; and more opinions

23-07-2012

Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

Affymax and Janssen Biotech enter $13 million peginesatide patent settlement

11-11-2011

US biotech firm Affymax (Nasdaq: AFFY) says it has reached a global settlement agreement with Janssen…

AffymaxBiotechnologyJanssen PharmaceuticaJohnson & JohnsonOncologyPatentspeginesatidePharmaceuticalTakeda Pharmaceuticals

Hematologist-oncologists view Velcade more favorably than Revlimid or Thalomid for multiple myeloma; report

01-11-2011

Current treatment options for multiple myeloma focus on the use of Takeda/Millennium/Janssen-Cilag’s…

carfilzomibCelgeneelotuzumabJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalpomalidomideRevlimidTakeda PharmaceuticalsThalomidVelcade

Sanofi to top Pfizer as number one for global pharma sales

01-11-2011

French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

Company Spotlight

ImmunoGen

ImmunoGen

Back to top